Press release
Intratumoral Cancer Therapies Market Set to Grow with a Remarkable CAGR of 31.3% Through 2034, Driven by Revolutionary Advances in Oncolytic Viral Therapy Pipeline | DelveInsight
Intratumoral Cancer Therapies Market Insights, Epidemiology, and Market Forecast – 2034
DelveInsight's "Intratumoral Cancer Therapies Market Insights, Epidemiology, and Market Forecast - 2034 [https://www.delveinsight.com/report-store/intratumoral-cancer-therapies-market-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report delivers an in-depth understanding of the intratumoral cancer therapies market, historical and forecasted epidemiology, as well as market trends across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. The report comprehensively evaluates the current treatment practices, emerging drugs, market share of individual therapies, and intratumoral cancer therapies market forecasts through 2034, providing crucial insights for stakeholders in the oncology therapeutic area.
According to DelveInsight's analysis, the intratumoral cancer therapies market is projected to witness exponential growth at a remarkable CAGR of 31.3% during the study cperiod 2020-2034 in the 7MM, driven by the anticipated approval of novel therapies with potential to transform "cold tumors" into "hot tumors," thereby facilitating immune system targeting of cancer cells. Furthermore, the United States is expected to capture the maximum chunk of the intratumoral cancer therapy market share.
Download the Intratumoral Cancer Therapies Market report to understand which factors are driving the therapeutic market @ Intratumoral Cancer Therapies Market Trends [https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
According to DelveInsight's estimates, the total intratumoral cancer patient pool across 7MM in 2024 were 3.3 million, which is expected to grow significantly during the forecast period.
The DelveInsight report categorizes intratumoral cancer therapies into several segments, including total cases of selected indications, indication-wise target patient pool of intra-tumoral cancer therapies and indication-wise treated cases of intra-tumoral cancer therapies.
Discover evolving trends in the Intratumoral Cancer Therapies patient pool forecasts @ Intratumoral Cancer Therapies Epidemiology Analysis [https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Intra-tumoral immunotherapy is gaining momentum as a targeted cancer treatment approach, offering localized immune activation with reduced systemic side effects. The first approved therapy in this space, Amgen's IMLYGIC (T-Vec), received US FDA approval for unresectable melanoma and later European approval in 2015. However, despite its innovative approach, IMLYGIC struggled commercially due to limited overall survival benefits and competition from immune checkpoint inhibitors. Other advances include Nanobiotix's HENSIFY (NBTXR3), approved in Europe for soft tissue sarcoma, and Japan's conditional approval of DELYTACT (G47) for malignant glioma, marking a significant step forward in oncolytic viral therapies.
According to the DelveInsight report, the intratumoral cancer therapies pipeline is rapidly expanding, with several promising candidates advancing toward regulatory milestones. Replimune's lead candidate RP1 (vusolimogene oderparepvec), developed using a proprietary Herpes Simplex Virus (HSV) platform, received FDA Breakthrough Therapy Designation in November 2024 with combination with Bristol Myers Squibb's nivolumab for advanced melanoma. Philogen, in collaboration with Sun Pharmaceutical, achieved EMA validation of its Marketing Authorization Application (MAA) in July 2024 for Nidlegy (L19IL2 + L19TNF), a novel skin cancer therapy. Candel Therapeutics is preparing for a Biologics License Application (BLA) submission by Q4 2026 for CAN-2409, an adenoviral immunotherapy targeting prostate cancer.
Other key players driving innovation include Lytix Biopharma and Verrica Pharmaceuticals with LTX-315 (VP-315), CEL-SCI with MULTIKINE, Highlight Therapeutics with BO-112, Cytovation ASA with CY-101, Intensity Therapeutics with INT230-6, Ascendis Pharma with TransCon IL-2 , Treovir and Matica Biotechnology with G207, QBiotics with Tigilanol tiglate, NanOlogy with NanoPac, EpicentRx with AdAPT-001, and Medicenna Therapeutics with Bizaxofusp (MDNA55). As these next-generation therapies advance, they are set to revolutionize the intra-tumoral cancer treatment landscape, offering novel therapeutic options and setting new standards in oncology care.
In early 2025, several key developments underscored the growing momentum in the intratumoral cancer therapies market. In March, Nanobiotix (EPA:NANO) announced topline results from the dose-escalation portion of a Phase I trial evaluating JNJ-1900 (NBTXR3), activated by radiation therapy, as a second-line or later treatment for locally advanced NSCLC in patients eligible for re-irradiation. That same month, Nanobiotix amended its global licensing agreement with Janssen Pharmaceutical, removing its funding obligation for the NANORAY-312 trial and waiving select future milestone payments from Johnson & Johnson, while preserving the potential for significant future revenue.
Also in March, Candel Therapeutics (NASDAQ:CADL) entered a strategic commercial partnership with IDEA Pharma, which will support the development and commercialization of CAN-2409. In January 2025, Lokon Pharma AB received Fast Track Designation (FTD) from the FDA for LOAd703, its candidate for the treatment of pancreatic cancer. Around the same time, Intensity Therapeutics (NASDAQ:INTS) announced that its Data Monitoring Committee (DMC) recommended the continuation of its Phase III sarcoma trial (INVINCIBLE-3) evaluating INT230-6, based on favorable data from the July to December
Discover recent advancements in the Intratumoral Cancer Therapies treatment landscape @ Intratumoral Cancer Therapies Recent Developments [https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The intratumoral cancer therapies market is highly competitive, with major players including Nanobiotix (EPA:NANO), Sirnaomics (HKEX:2257), Apexigen (NASDAQ:APGN), Replimune (NASDAQ:REPL), Merck & Co (NYSE:MRK), Highlight Therapeutics, OncoSec Medical (NASDAQ:ONCS), Intensity Therapeutics (NASDAQ:INTS), DNAtrix, Treovir, Philogen, Lokon Pharma AB, Regeneron (NASDAQ:REGN), Istari Oncology, Pfizer (NYSE:PFE), Bristol-Myers Squibb (NYSE:BMY), Biogen (NASDAQ:BIIB), Immunovative Therapeutics, Idera Pharmaceuticals, Roche (SWX:ROG), Sanofi (EPA:SAN), Boehringer Ingelheim, and Daiichi Sankyo (TYO:4568), all advancing diverse therapeutic approaches through robust R&D and strategic collaborations.
Looking ahead, the intratumoral cancer therapies market is expected to witness continued innovation driven by advancements in early detection technologies, integration of artificial intelligence in cancer diagnosis, and personalized medicine approaches. The rising incidence of cancer, with over 1.95 million new cases reported in 2023, continues to fuel market growth. Emerging therapies focusing on novel mechanisms, including oncolytic viruses, immunomodulators, and gene-based approaches, hold promise for addressing unmet medical needs [https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr] and transforming the treatment landscape.
DelveInsight's analysis underscores that despite current therapeutic limitations, substantial opportunities remain for developing more effective, targeted treatment options that can achieve durable responses and improved overall survival for cancer patients worldwide. As research accelerates and regulatory frameworks evolve, the intratumoral cancer therapies market is positioned for remarkable expansion and therapeutic breakthroughs through 2034.
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Intratumoral Cancer Therapies Market Overview at a Glance
5. Epidemiology and Market Forecast Methodology
6. Key Events
7. Intratumoral Cancer Therapies Background and Overview
8. Intratumoral Cancer Therapies Treatment
9. Intratumoral Cancer Therapies Epidemiology and Patient Population in the 7MM
10. Intratumoral Cancer Therapies Patient Journey
11. Intratumoral Cancer Therapies Marketed Drug
12. Intratumoral Cancer Therapies Emerging Drugs
13. Intratumoral Cancer Therapies: 7MM Analysis
14. Unmet needs
15. SWOT Analysis
16. KOL Views
17. Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=intratumoral-cancer-therapies-market-set-to-grow-with-a-remarkable-cagr-of-313-through-2034-driven-by-revolutionary-advances-in-oncolytic-viral-therapy-pipeline-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Intratumoral Cancer Therapies Market Set to Grow with a Remarkable CAGR of 31.3% Through 2034, Driven by Revolutionary Advances in Oncolytic Viral Therapy Pipeline | DelveInsight here
News-ID: 4084081 • Views: …
More Releases from ABNewswire
Adapts.ai Redefines Software Maintenance and Modernization with GenAI-Powered Pl …
October 10, 2025 - In an era where digital transformation defines competitive advantage, Adapts.ai is emerging as a game-changer in enterprise application modernization and AI-driven digital transformation services. The platform leverages next-generation GenAI technology to simplify software maintenance, accelerate legacy code modernization, and empower engineering teams with intelligent automation.
Adapts addresses one of the most pressing challenges in modern software engineering - navigating outdated, poorly documented, and complex legacy codebases. Traditional…
A Journey Across Oceans and Generations: "From Germany With Love" Uncovers One F …
Julie Anne Brion never set out to write a history book. What she did want was to understand where she came from, and maybe, just maybe, help others feel a little less lost in their own search for belonging. The result is her newest book, From Germany With Love: Mit Liebe aus Deutschland , a deeply personal look at one family's journey from the heart of Europe to the promise…
New Book from Immigration Attorney Shares Practical Guidance for Securing a U.S. …
New York, NY - Immigrants working toward permanent residency in the United States now have a new guide to help them through the process. Anne Zeitoun-Sedki, an immigration attorney with more than 15 years of hands-on experience, whose YouTube channel has attracted millions of views worldwide, has published a book that simplifies the path to a U.S. green card.
The book draws on Zeitoun-Sedki's years of representing individuals and families from…
Kinghelm Antennas Power OBD Applications in Smart and New Energy Vehicles
Kinghelm, a leading RF and microwave technology company, provides high-performance antennas and connectors for OBD systems in smart and new energy vehicles. Together with partners Slkor Semiconductor and Avant Electronics, Kinghelm delivers integrated solutions for GPS/BDS positioning, Bluetooth/Wi-Fi transmission, and intelligent vehicle connectivity.
Image: https://www.abnewswire.com/upload/2025/10/0790f023c90e731790a4ec80533af9ea.jpg
Automotive OBD Products and Application Scenarios
As intelligent connected vehicles become increasingly mainstream, On-Board Diagnostics (OBD) systems have emerged as a vital component for ensuring driving safety, emissions…
More Releases for Intratumoral
Intratumoral Cancer Therapies Market Key Players, Share and Forecast Outlook
Introduction
The global intratumoral cancer therapies market is gaining momentum as oncology research pivots towards more localized, targeted treatment modalities. Unlike systemic therapies, intratumoral approaches deliver drugs or immuno-stimulants directly into the tumor site, enhancing efficacy while minimizing systemic toxicity. With rising cancer prevalence, rapid advancements in drug delivery technologies, and growing clinical validation for combination therapies, the market is expected to experience strong expansion through 2034. This approach is especially…
Intratumoral Cancer Therapies Market Outlook 2024 to 2034
Market Overview
The Intratumoral Cancer Therapies Market represents a highly innovative segment of oncology, focusing on direct delivery of therapeutics into tumors to enhance local immune responses and minimize systemic toxicity. With oncology shifting toward precision and localized treatments, intratumoral therapies are becoming a cornerstone in immuno-oncology pipelines.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/59109
Key Highlights:
• Market Size (2024): USD 1.03 billion
• Forecast (2034): USD 2.82 billion
• CAGR (2024-2034): 10.7%
• Key Drivers: Rising cancer…
Driving Intratumoral Cancer Therapies Market Growth in 2025: The Role of Rising …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
Intratumoral Cancer Therapies Market Size Growth Forecast: What to Expect by 2025?
The market size of intratumoral cancer therapies has seen notable development in the last few years. The market size will increase from $140 billion in 2024 to $158.38 billion in 2025, boasting a compound annual growth rate (CAGR) of 13.1%. Reasons for…
Intratumoral Cancer Therapies Market Report 2024 - Intratumoral Cancer Therapies …
"The Business Research Company recently released a comprehensive report on the Global Intratumoral Cancer Therapies Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The intratumoral cancer therapies…
Intratumoral Cancer Therapies Market Report 2024: Growth, Trends, Analysis, Dema …
"The new report published by The Business Research Company, titled ""Intratumoral Cancer Therapies Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the intratumoral cancer therapies market size has grown rapidly in recent years. It will grow from $124.82 billion…
Intratumoral Cancer Therapies Market Growth Analysis, Outlook Report 2024-2033
The intratumoral cancer therapies market size has grown rapidly in recent years. It will grow from $124.82 billion in 2023 to $141.55 billion in 2024 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to advancements in cancer research, increasing cancer incidence, demand for precision medicine, clinical evidence and research initiatives, unmet medical needs..
The intratumoral cancer therapies market size…
